Abstract Over the past decade and a half, psychedelic drug-induced experiences have been returning to psychiatry as promising new healing modalities. The case of psychedelic-assisted
Psychedelic or ecodelic medicines (e.g., psilocybin, ayahuasca, iboga) for the care and treatment of addiction, post-traumatic stress disorder, cancer, cluster headaches, anxiety, and depression have
Abstract The term “corporadelic” signifies “manifesting corporate structures, ethos, or logic within the context of the psychedelic landscape.” It points to a relatively novel
Abstract Psychedelic compounds are on the cusp of being approved by medical regulators for treatment-resistant mental health disorders. Following promising clinical trials, and as
This commentary considers efforts to turn psychedelics into medications that can be administered through healthcare systems as examples of “medicalization.” I draw on ethnographic research
©2025 Unlimited Sciences. All rights reserved.